 |
|
Pneumococcal conjugate vaccines: choice of schedule and product development
Jin Lee
Clin Exp Pediatr. 2020;63(7):259-260. Published online 2020 Apr 27 DOI: https://doi.org/10.3345/cep.2019.01739
|
|
Citations to this article as recorded by
 Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses
Mary Kline, Anne L. Wyllie, Kathleen McElwee, James Trammel, Ayman Sabra, Calman A. MacLennan, Christian Theilacker, Jennifer C. Moïsi
Pediatric Infectious Disease Journal.2026;[Epub] CrossRef Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review
Vijay Yewale, Pallab Chatterjee, Sanjay M. Marathe, Santosh Taur, Sripriya Sathyanarayanan
Human Vaccines & Immunotherapeutics.2025;[Epub] CrossRef Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2+1 schedule
Shahrul Mt-Isa, Justin R. Chumbley, Matthew S. Kelly, Jessica Weaver, Natalie Banniettis
Expert Review of Vaccines.2025; 24(1): 946. CrossRef Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
Josiah Ryman, Jeffrey R. Sachs, Natalie Banniettis, Thomas Weiss, Maurice Ahsman, Ka Lai Yee, Jessica Weaver
Expert Review of Vaccines.2024; 23(1): 467. CrossRef
|